🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity - check out this review from The Francis Crick Institute Julian Downward & Miriam Molina Arcas in Cancer Cell #AACR24 hubs.li/Q02rwVbs0

Local T cell neighbourhoods determine outcome in non-small cell lung cancer treatment with KRAS-G12C inhibitors. Timely and relevant work from Megan Cole and Panayiotis Anastasiou from the @JulianDownwardlab, and Claudia Lee from the Swanton Lab. doi.org/10.1101/2024.0…

Very excited to share our latest work, out today in Science Magazine, on the serendipitous finding that vitamin D ☀️ regulates the gut microbiome to promote cancer immunity🦠 science.org/doi/10.1126/sc… 🧵👇 Caetano Reis e Sousa The Crick

🌟Pleased to share our review on Metastatic Colorectal Cancer Nature Reviews Gastroenterology & Hepatology Adrià Cañellas Socias Elena Sancho 👉🏻nature.com/articles/s4157…

We are looking for a post-doc with a background in immunology to work on the impact of RAS oncogenic signaling on the interaction of lung cancers with the immune system. Fully funded four year position at Francis Crick Institute in London. #Crick crick.wd3.myworkdayjobs.com/External/job/L…

Pleased to share our latest work from Miriam Merad, MD, PhD lab Lipschultz Precision Immunology Institute, where we try to address the Q: Do tumors alter the epigenetic state of myeloid progenitors in marrow, and are certain aspects of immunosuppressive mono-macrophage fate sealed before they enter the tumor?🧵

Great news! NUJ Nature journals and Springer Nature are pleased to have reached an agreement that ends our pay dispute through a two-year settlement and would like to pay tribute to the mutual efforts that helped us find a way forward.

How does oncogenic KRAS impact anti-tumor immunity in lung cancer? Out now in Cancer Research, using CRISPR screening we uncover COX-2/PGE2 signalling as a major mediator of immunotherapy resistance driven by oncogenic KRAS signaling. Jesse Boumelha The Crick aacrjournals.org/cancerres/arti…

Just before the summer break! Very proud and excited to share our latest work on tumor macrophage ontogeny ! Spatial temporal regulation of TAM development revealed using time stamping approaches! Ms4a3 Creert2 is a gem! science.org/doi/10.1126/sc…, congratulations to the team!

Paper 🚨! Ecstatic, proud, grateful …Years of dedication from the whole lab, with the exceptional Daan J. Kloosterman and the one of a kind #JohannaErbani at its helm. What a journey all the way to Cell! How did it start (& end)? A 🧵1/n cell.com/cell/fulltext/…

Thrilled to share our first study on aging from Miriam Merad, MD, PhD lab Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute Lipschultz Precision Immunology Institute in which we demonstrate how aging promotes cancer. We show that: (1/n) science.org/doi/10.1126/sc…

How can we extend responses to KRASG12C drugs? Out now in Nature Communications, combining Revolution Medicines’ RAS(ON) G12C-selective inhibitor with a SHP2 inhibitor and immune checkpoint blockade to study their effects on KRAS-mutant lung tumours of varying immunogenicities.

I had the most extraordinary celebration of my Lab 20th anniversary this weekend in the Poconos (aka 'Mykonos' to the labbies !) Thanks to Jessica Le berichel for the extraordinary organization and Samarth Hegde and Jesse Boumelha for the scientific leadership (1x)

Very grateful to Cancer Cell for thoroughly spotlighting our work on hematopoietic aging, IL-1 and DNMT3A, and their vital roles in aging-driven tumor progression! Read the spotlight: doi.org/10.1016/j.ccel… View our paper: science.org/doi/10.1126/sc…

In our new paper just out in Science Advances we investigate mechanisms that may be limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy. science.org/doi/10.1126/sc…

Hot off the press!! 🔥 Check out our work on the origins and impact of ecDNA. This was a team effort involving multiple collaborators as one of a three part series on ecDNA in nature

So excited to share our new paper out in nature led by the fabulous Anais Elewaut and Guillem Estivill providing mechanistic insights into anti-tumor immunity and why it may fail in so many patients! Sky-torial on Anna Obenauf.bsky.social rdcu.be/d1F7s

I am thrilled to share a new story, co-led w Meriem Belabed from Miriam Merad, MD, PhD lab Lipschultz Precision Immunology Institute Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute on our discovery of how cholesterol is used by DCs to undergo maturation. See our new study Nature Immunology : nature.com/articles/s4159…

I'm excited to share a new review Nature Reviews Cancer from Miriam Merad, MD, PhD lab Lipschultz Precision Immunology Institute led by X-less Chang Moon. We offer one of the most comprehensive reviews of DC functions, phenotypes, and maturation at steady-state and in cancer. It is a must-read! doi.org/10.1038/s41568…

Few open spots left for our FREE online International 🎓 Immunoschool 🎓! Join leading immunologists Monday, March 10—for an exclusive deep dive into the cutting-edge research behind the most successful immunotherapies and what's on the horizon. SIGN UP: loom.ly/HJdSGlw